(Q37661476)

21 August 2017

1 reference

title

Progress in defining optimal treatment outcome in schizophrenia (English)

1 reference

21 August 2017

0 references

1

Gary Remington

1 reference

21 August 2017

3

Ofer Agid

1 reference

21 August 2017

2

George Foussias

1 reference

21 August 2017

publication date

1 January 2010

1 reference

21 August 2017

1 reference

21 August 2017

volume

24

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

9-20

1 reference

https://scigraph.springernature.com/pub.10.2165/11530250-000000000-00000

21 August 2017

exact match

0 references

cites work

Negative v positive schizophrenia. Definition and validation.

1 reference

https://api.crossref.org/works/10.2165%2F11530250-000000000-00000

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530250-000000000-00000

Deterioration in premorbid functioning in schizophrenia: a developmental model of negative symptoms in drug-free patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530250-000000000-00000

The prodromal phase of first-episode psychosis: past and current conceptualizations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530250-000000000-00000

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530250-000000000-00000

Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530250-000000000-00000

Identifying subtypes of schizophrenia by cluster analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530250-000000000-00000

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530250-000000000-00000

Treatment outcomes in schizophrenia: implications for practice, policy, and research

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530250-000000000-00000

UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530250-000000000-00000

Detecting improvement in quality of life and symptomatology in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530250-000000000-00000

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11530250-000000000-00000

Longitudinal studies of outcome and recovery in schizophrenia and early intervention: can they make a difference?

21 January 2018

1 reference

12 December 2020

Treatment-resistant schizophrenia

1 reference

12 December 2020

A review of instruments developed to measure outcomes for carers of people with mental health problems

1 reference

12 December 2020

Performance-based measures of functional skills: usefulness in clinical treatment studies

1 reference

12 December 2020

The NIMH-MATRICS consensus statement on negative symptoms

1 reference

12 December 2020

Positive and negative schizophrenic symptoms and the role of dopamine

1 reference

12 December 2020

Psychiatric comorbidities and schizophrenia

1 reference

12 December 2020

Early use of clozapine for poorly responding first-episode psychosis.

1 reference

12 December 2020

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

1 reference

12 December 2020

What the CATIE study means for clinical practice

1 reference

12 December 2020

Remission criteria for schizophrenia: evaluation in a large naturalistic cohort

1 reference

12 December 2020

Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial

1 reference

12 December 2020

EPS profiles: the atypical antipsychotics are not all the same

1 reference

12 December 2020

A depression rating scale for schizophrenics

1 reference

12 December 2020

Negative symptoms in schizophrenia: avolition and Occam's razor

1 reference

12 December 2020

Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study

1 reference

12 December 2020

Emerging drugs for schizophrenia

1 reference

12 December 2020

Do consumers use the word "recovery"?

1 reference

12 December 2020

Extrapyramidal side-effects of antipsychotics in a randomised trial

1 reference

12 December 2020

Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.

1 reference

12 December 2020

Schizophrenia: from developmental deviance to dopamine dysregulation

1 reference

12 December 2020

Recovery from schizophrenia: a concept in search of research

1 reference

12 December 2020

Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.

1 reference

12 December 2020

Relapse prevention and recovery in the treatment of schizophrenia

1 reference

12 December 2020

Understanding antipsychotic "atypicality": a clinical and pharmacological moving target

1 reference

12 December 2020

Negative symptoms of schizophrenia: a problem that will not go away

1 reference

12 December 2020

At issue: is natural selection rendering schizophrenia less severe?

1 reference

12 December 2020

Molecular targets for treating cognitive dysfunction in schizophrenia.

1 reference

12 December 2020

Relationship of cognition and psychopathology to functional impairment in schizophrenia

1 reference

12 December 2020

Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol

1 reference

12 December 2020

Evidence-based pharmacotherapy of schizophrenia

1 reference

12 December 2020

Measures of quality of life among persons with severe and persistent mental disorders

1 reference

12 December 2020

Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis

1 reference

12 December 2020

Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study.

1 reference

12 December 2020

The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials.

1 reference

12 December 2020

Unanswered questions in schizophrenia clinical trials

1 reference

12 December 2020

Tardive dyskinesia and new antipsychotics

1 reference

12 December 2020

Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim

1 reference

12 December 2020

The top ten concerns about recovery encountered in mental health system transformation

1 reference

12 December 2020

Subjective effects of antipsychotic drugs and their relevance for compliance and remission.

1 reference

12 December 2020

Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study

1 reference

12 December 2020

Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.

1 reference

12 December 2020

Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia

1 reference

12 December 2020

Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia

1 reference

12 December 2020

Social context and health consequences of the antipsychotics introduction

1 reference

12 December 2020

A historical perspective of clozapine.

1 reference

12 December 2020

Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders

1 reference

12 December 2020

Cognitive function in schizophrenic patients

1 reference

12 December 2020

Validation of remission criteria for schizophrenia.

1 reference

12 December 2020

Tardive dyskinesia circa 2006

1 reference

12 December 2020

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

1 reference

12 December 2020

The predictive value of measures of social cognition for community functioning in schizophrenia: implications for neuropsychological assessment.

1 reference

12 December 2020

Defining and measuring clinical effectiveness in the treatment of schizophrenia

1 reference

12 December 2020

Symptom remission in first episode patients

1 reference

12 December 2020

The cognitive efficacy of atypical antipsychotics in schizophrenia

1 reference

12 December 2020

Testing Liddle's three-syndrome model in families with schizophrenia

1 reference

12 December 2020

Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.

1 reference

12 December 2020

Cognitive remediation: a promising tool for the treatment of schizophrenia

1 reference

12 December 2020

Remission in the outpatient care of schizophrenia: 3-year results from the Schizophrenia Outpatients Health Outcomes (SOHO) study in France

1 reference

12 December 2020

On the concept of remission in schizophrenia.

1 reference

12 December 2020

A review of instruments for measuring functional recovery in those diagnosed with psychosis

1 reference

12 December 2020

Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?

1 reference

12 December 2020

Definitions of the term 'recovered' in schizophrenia and other disorders

1 reference

12 December 2020

Linking the PANSS, BPRS, and CGI: clinical implications

1 reference

12 December 2020

Commentary: disquieting aspects of the recovery paradigm.

1 reference

12 December 2020

Commentary: all we are saying is give people with mental illnesses a chance.

1 reference

12 December 2020

Novel antipsychotics and negative symptoms

1 reference

12 December 2020

Long-term outcome of patients with schizophrenia: a review

1 reference

12 December 2020

The Schedule for the Deficit syndrome: an instrument for research in schizophrenia.

1 reference

12 December 2020

The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions.

1 reference

12 December 2020

Elementary neurocognitive function, facial affect recognition and social-skills in schizophrenia

1 reference

12 December 2020

Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

12 December 2020

Negative symptoms and cognitive deficits: what is the nature of their relationship?

1 reference

12 December 2020

Pathophysiology and treatment of negative symptoms.

1 reference

12 December 2020

Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up.

1 reference

12 December 2020

Remission: what's in a name?

1 reference

12 December 2020

Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs

1 reference

12 December 2020

A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

1 reference

12 December 2020

Remission in schizophrenia: Applying recent consensus criteria to refine the concept

1 reference

12 December 2020

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

1 reference

12 December 2020

Augmentation strategies in clozapine-resistant schizophrenia

1 reference

12 December 2020

Association between symptomatic remission and functional outcome in first-episode schizophrenia.

1 reference

12 December 2020

Schizophrenia, symptomatology and social inference: investigating "theory of mind" in people with schizophrenia.

1 reference

12 December 2020

Preferences for schizophrenia treatment outcomes among public policy makers, consumers, families, and providers

1 reference

12 December 2020

Vulnerability to relapse in schizophrenia

1 reference

12 December 2020

History of the discovery and clinical introduction of chlorpromazine

1 reference

12 December 2020

Barriers to employment for people with schizophrenia

1 reference

12 December 2020

Functional outcomes in schizophrenia.

1 reference

12 December 2020

Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group

1 reference

12 December 2020

The concepts of remission and recovery in schizophrenia

1 reference

12 December 2020

Selection of outcome assessment instruments for inpatients with severe and persistent mental illness

1 reference

12 December 2020

Cognitive function in schizophrenia--do neuroleptics make a difference?

1 reference

12 December 2020

The MATRICS initiative: developing a consensus cognitive battery for clinical trials.

1 reference

12 December 2020

Atypical antipsychotics: are some more atypical than others?

1 reference

12 December 2020

Comparative remission rates of schizophrenic patients using various remission criteria

1 reference

12 December 2020

Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy.

1 reference

12 December 2020

Standardized remission criteria in schizophrenia

1 reference

12 December 2020

Measuring the effectiveness of outpatient care.

1 reference

12 December 2020

Deficit and nondeficit forms of schizophrenia: the concept

1 reference

12 December 2020

New generation antipsychotic drugs and compliance behaviour

1 reference

12 December 2020

Rationale for emphasis on management over treatment of schizophrenia in clinical practice.

1 reference

12 December 2020

Drug initiatives to improve cognitive function.

1 reference

12 December 2020

The pipeline and future of drug development in schizophrenia.

1 reference

12 December 2020

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

12 December 2020

Depression in schizophrenia: a comparison of three measures

1 reference

12 December 2020

Social cognitive impairments in first episode psychosis.

1 reference

12 December 2020

Is it possible to be schizophrenic yet neuropsychologically normal?

1 reference

12 December 2020

Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

12 December 2020

The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis

1 reference

12 December 2020

Health status of individuals with serious mental illness

1 reference

12 December 2020

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

12 December 2020

Improving adherence to antipsychotic pharmacotherapy

1 reference

12 December 2020

Measuring illness management outcomes: a psychometric study of clinician and consumer rating scales for illness self management and recovery

1 reference

12 December 2020

Subjective and objective quality of life in schizophrenia

1 reference

12 December 2020

What is relapse in schizophrenia?

1 reference

12 December 2020

The role of 5-HT2A receptors in antipsychotic activity

1 reference

12 December 2020

First-episode psychosis, early intervention, and outcome: what have we learned?

1 reference

12 December 2020

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

1 reference

12 December 2020

Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia.

1 reference

12 December 2020

Recent advances in shared decision making for mental health

1 reference

12 December 2020

The clinical relevance of percentage improvements on the PANSS score.

1 reference

12 December 2020

How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia

1 reference

12 December 2020

Schizophrenia: improving outcome

1 reference

12 December 2020

Examining the latent structure of negative symptoms: is there a distinct subtype of negative symptom schizophrenia?

1 reference

12 December 2020

The paradox of normal neuropsychological function in schizophrenia

1 reference

12 December 2020

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

12 December 2020

Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment.

1 reference

12 December 2020

Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining?

1 reference

12 December 2020

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

12 December 2020

Schizophrenia and increased risks of cardiovascular disease

1 reference

12 December 2020

10.2165/11530250-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

21 August 2017

1002527401

0 references

1 reference